Ebunat 0.5mg Injection

Ebunat 0.5mg Injection contains Eribulin Mesylate (0.5 mg). Eribulin Mesylate is a microtubule dynamics inhibitor used mainly for the treatment of some cancers such as metastatic breast cancer and liposarcoma. Eribulin is a derivative of a naturally occurring product from a marine sponge that inhibits cancer cells’ ability to divide by disrupting microtubule function.

Uses of Ebunat 0.5mg Injection

• Metastatic Breast Cancer
• Metastatic Liposarcoma

How does the Ebunat 0.5mg Injection work?

Eribulin interferes with the growing phase of microtubules (important components of the cellular skeleton) and inhibits cancer cells from dividing, leading to cell death.

How to Use & Dosage

Eribulin injection comes as a solution (liquid) to be injected intravenously (into a vein) by a doctor or nurse in a hospital, infusion center, or doctor’s office over a period of 2 to 5 minutes. It is usually given on day 1 and day 8 of a 21-day cycle.

Your doctor may need to lower your dose or delay your treatment if you develop specific side effects. Make sure you tell your doctor how you feel during your treatment.

Possible Side Effects

• Fatigue
• Nausea
• Constipation
• Hair loss
• Weakness
• Numbness or tingling in hands and feet
• Fever
• Anemia
• Decreased appetite

Safety Advise

🫀 Liver

Dosing in patients with liver disease may need to be adjusted. Liver function tests need to be performed regularly. Please talk to your healthcare provider.

🫘 Kidney

Dose adjustments may be necessary in patients with renal impairment. Regular testing for kidney function should be done. Please consult with your health care provider.

🤰 Pregnancy

Eribulin should not be used in pregnancy as it may harm the unborn baby. Please discuss with your health care provider.

🤱 Breast Feeding

Eribulin may pass into breast milk and could be harmful to a baby. Do not breast-feed while you are taking this medication. Discuss with your doctor.

🍺 Alcohol

It is not known whether it is safe to drink alcohol when you have Ebunat 0.5mg Injection. Discuss with your healthcare provider.

Storage Instructions

Store vials under refrigeration at 2°C to 8°C (36°F to 46°F). Don’t freeze.

References

• Malleswari PN, Gupta PV, Vardhan SV, Ramachandran D. Quantitative estimation of ethanol content in eribulin mesylate injection using headspace gas chromatographic with flame ionization detector (HS-GC-FID). The Scientific Temper. 2024 Jun 15;15(02):2039-44.
• Huyck TK, Gradishar W, Manuguid F, Kirkpatrick P. Eribulin mesylate. Nature Reviews Drug Discovery. 2011 Mar 1;10(3):173.
• Dybdal-Hargreaves NF, Risinger AL, Mooberry SL. Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent. Clinical Cancer Research. 2015 Jun 1;21(11):2445-52.
• Cigler T, Vahdat LT. Eribulin mesylate for the treatment of breast cancer. Expert Opinion on Pharmacotherapy. 2010 Jun 1;11(9):1587-93.
• Aseyev O, Ribeiro JM, Cardoso F. Review on the clinical use of eribulin mesylate for the treatment of breast cancer. Expert Opinion on Pharmacotherapy. 2016 Mar 3;17(4):589-600.

Disclaimer

IHS Enterprises’s primary objective is to guarantee the accuracy, reliability, and specialist review of the information it provides to customers. The contents and information provided on this website are for informational purposes only. They should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician for guidance and any questions you may have about any condition or medication. If you do read anything from IHS Enterprises, please do not discount or delay in seeking competent medical advice. We want to enhance the doctor-patient relationship, not substitute it.

Manufacturer Details

Name: Natco Pharma Ltd

Address: Natco House, Road No. 2, Banjara Hills, Hyderabad – 500034, India

Country of origin: India